Received Aug 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
A 15-year-old male patient received two doses of the vaccine 14 years ago, 1 month apart instead of between 6 to 12 months later as recommended; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 15-year-old male patient who received HAV (Havrix) for prophylaxis. Concomitant products included Hepatitis a vaccine inact (Havrix). On 01-JAN-2011, the patient received the 2nd dose of Havrix. On an unknown date, an unknown time after receiving Havrix, the patient experienced drug dose administration interval too short (Verbatim: A 15-year-old male patient received two doses of the vaccine 14 years ago, 1 month apart instead of between 6 to 12 months later as recommended). The outcome of the drug dose administration interval too short was not applicable. Additional Information: GSK Receipt Date: 23-JUL-2025 The pharmacist called to get assistance on the Havrix vaccine series. A 15-year-old male patient received two doses of the vaccine 14 years ago, 1 month apart instead of between 6 to 12 months later as recommended which led to shortening of vaccination schedule. The reporter called to know if a new second dose should be administered or if the complete series was required again. Not enough information was collected for this adverse event. The pharmacist refused to provide more information.
Havrix